Cargando…
2417. Risk Factors, Response to Empiric Therapy, and Healthcare Utilization Among Children With UTI Due to Extended Spectrum β-Lactamase-Producing Enterobacteriaceae
BACKGROUND: There are few data on risk factors, chosen therapy and healthcare utilization among US children with extended spectrum β lactamase-positive urinary tract infection (ESBL UTI). We performed a multicenter case–control study on childhood ESBL UTI from November 2014 to February 2017; herein...
Autores principales: | Dasgupta-Tsinikas, Shom, Zangwill, Kenneth, Van, Tam, Friedlander, Scott, Yeh, Sylvia H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253341/ http://dx.doi.org/10.1093/ofid/ofy210.2070 |
Ejemplares similares
-
1452. Is Carbapenem-Sparing Therapy as Effective as Carbapenems Against Extended-Spectrum β-Lactamase Producing Enterobacteriaceae in UTI?
por: Hyun, Jonghoon, et al.
Publicado: (2019) -
Risk Factors for Community Acquired Extended-Spectrum Β-lactamase (ESBL) Producing Enterobacteriaceae Urinary Tract Infections (UTIs)
por: Goyal, Dheeraj, et al.
Publicado: (2017) -
Extended-spectrum β-lactamase-producing and carbapenemase-producing Enterobacteriaceae
por: Wilson, Hayley, et al.
Publicado: (2018) -
Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae in Fresh Produce
por: Pintor-Cora, Alberto, et al.
Publicado: (2021) -
Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
por: Ng, Tat Ming, et al.
Publicado: (2016)